These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 18688283)

  • 101. Development of a Cell-Based Assay for Identifying K
    Jakakul C; Kanjanasirirat P; Muanprasat C
    SLAS Discov; 2021 Mar; 26(3):439-449. PubMed ID: 32830616
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Downregulation of IL-8 and IL-10 by the Activation of Ca
    Ohya S; Matsui M; Kajikuri J; Kito H; Endo K
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955737
    [TBL] [Abstract][Full Text] [Related]  

  • 103. The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.
    Lam J; Wulff H
    Drug Dev Res; 2011 Nov; 72(7):573-584. PubMed ID: 22241939
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Senicapoc: Repurposing a Drug to Target Microglia K
    Staal RGW; Weinstein JR; Nattini M; Cajina M; Chandresana G; Möller T
    Neurochem Res; 2017 Sep; 42(9):2639-2645. PubMed ID: 28364331
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels.
    Lambertsen KL; Gramsbergen JB; Sivasaravanaparan M; Ditzel N; Sevelsted-Møller LM; Oliván-Viguera A; Rabjerg M; Wulff H; Köhler R
    PLoS One; 2012; 7(10):e47744. PubMed ID: 23077667
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Preventing stenosis by local inhibition of KCa3.1: a finger on the phenotypic switch.
    Lounsbury KM
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1036-8. PubMed ID: 18495973
    [No Abstract]   [Full Text] [Related]  

  • 107. Expression and Role of the Intermediate-Conductance Calcium-Activated Potassium Channel KCa3.1 in Glioblastoma.
    Catacuzzeno L; Fioretti B; Franciolini F
    J Signal Transduct; 2012; 2012():421564. PubMed ID: 22675627
    [TBL] [Abstract][Full Text] [Related]  

  • 108. LY294002 Inhibits Intermediate Conductance Calcium-Activated Potassium (KCa3.1) Current in Human Glioblastoma Cells.
    Caglioti C; Palazzetti F; Monarca L; Lobello R; Ceccarini MR; Iannitti RG; Russo R; Ragonese F; Pennetta C; De Luca A; Codini M; Fioretti B
    Front Physiol; 2021; 12():790922. PubMed ID: 35069252
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Immunofluorescence-based assay to identify modulators of the number of plasma membrane KCa3.1 channels.
    Balut CM; Gao Y; Luke C; Devor DC
    Future Med Chem; 2010 May; 2(5):707-13. PubMed ID: 20596245
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Can KCa3.1 channel activators serve as novel inhibitors of platelet aggregation?
    Wulff H; Braun AP; Alper SL
    J Thromb Haemost; 2022 Nov; 20(11):2488-2490. PubMed ID: 36271464
    [No Abstract]   [Full Text] [Related]  

  • 111. AGEs-RAGE-K
    Zhang Y; Ma XZ; Zhao XY; Li JJ; Ma S; Pang ZD; Xu J; Du XJ; Deng XL; Wang JH
    Heliyon; 2023 Apr; 9(4):e14823. PubMed ID: 37025887
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Role of SNARE Proteins in the Insertion of KCa3.1 in the Plasma Membrane of a Polarized Epithelium.
    Farquhar RE; Cheung TT; Logue MJE; McDonald FJ; Devor DC; Hamilton KL
    Front Physiol; 2022; 13():905834. PubMed ID: 35832483
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease.
    Maezawa I; Jenkins DP; Jin BE; Wulff H
    Int J Alzheimers Dis; 2012; 2012():868972. PubMed ID: 22675649
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.
    Wulff H; Castle NA
    Expert Rev Clin Pharmacol; 2010 May; 3(3):385-96. PubMed ID: 22111618
    [TBL] [Abstract][Full Text] [Related]  

  • 115. KCa3.1 Impairment Is Not Just a Slow Afterthought in Epilepsy.
    Gross C
    Epilepsy Curr; 2020; 20(4):211-213. PubMed ID: 34025230
    [No Abstract]   [Full Text] [Related]  

  • 116. Fused Thiazin-3-ones as KCa3.1 Inhibitors.
    Blass B
    ACS Med Chem Lett; 2014 May; 5(5):460-1. PubMed ID: 24900861
    [No Abstract]   [Full Text] [Related]  

  • 117. Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of human T cells.
    Chimote AA; Hajdu P; Kucher V; Boiko N; Kuras Z; Szilagyi O; Yun YH; Conforti L
    J Immunol; 2013 Dec; 191(12):6273-80. PubMed ID: 24227782
    [TBL] [Abstract][Full Text] [Related]  

  • 118. The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling.
    Bi D; Toyama K; Lemaître V; Takai J; Fan F; Jenkins DP; Wulff H; Gutterman DD; Park F; Miura H
    J Biol Chem; 2013 May; 288(22):15843-53. PubMed ID: 23609438
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Stage-specific Effects of Bioactive Lipids on Human iPSC Cardiac Differentiation and Cardiomyocyte Proliferation.
    Sharma A; Zhang Y; Buikema JW; Serpooshan V; Chirikian O; Kosaric N; Churko JM; Dzilic E; Shieh A; Burridge PW; Wu JC; Wu SM
    Sci Rep; 2018 Apr; 8(1):6618. PubMed ID: 29700394
    [TBL] [Abstract][Full Text] [Related]  

  • 120. KCa3.1 ion channel: A novel therapeutic target for corneal fibrosis.
    Anumanthan G; Gupta S; Fink MK; Hesemann NP; Bowles DK; McDaniel LM; Muhammad M; Mohan RR
    PLoS One; 2018; 13(3):e0192145. PubMed ID: 29554088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.